Eisai
Presence
Eisai is one of the...
Eisai is a company listed under the stock ticker 4523 (JP).
Eisai has a direct presence in 11 countries.Eisai has 12 subsidiaries including EA Pharma, Eisai Americas and Eisai Australia.
They are in:
Executives
View the org chart displaying its 98 main executives
Most searched biographies at Eisai
- Haruo Naito, Chief Executive Officer, Representative Executive Off...
- Yumiko Miwa, Director
- Ryota Miura, Director
Popular executive movements at Eisai
- Keisuke Naito who is Vice President and Chief Ecosystem Officer, will be promoted to Chief Strategy & Planning Officer, Chief Ecosystem Officer and Acting Global Alzheimer's Disease Officer on Jul. 31, 2023 (posted on July 12 2023).
- Ivan Cheung, Senior Vice President, Global Alzheimer's Disease Officer and President, Americas Region, will retire on Jul. 31, 2023 (posted on July 12 2023).
Create your alert
to follow the executive moves at Eisai.
Pharmaceuticals
Eisai has 1,881 competitors including Pfizer (United States (USA)), Johnson & Johnson (United States (USA)) and Roche (Switzerland).
Popular M&A news in Pharmaceuticals
- Biogen has acquired Reata Pharmaceuticals (posted on September 29 2023).
- Novo Holdings has announced the acquisition of Paratek Pharmaceuticals (posted on September 27 2023).
- Generate Biomedicines has just announced a $273 Million fundraising (posted on September 19 2023).
Popular contacts in Pharmaceuticals
News
Press releases by Eisai
- Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Two Phase 3 Trials Evaluating LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer | News Release：2023 | Eisai Co., Ltd.
- RELEASE OF DEMENTIA DISEASE AWARENESS VIDEOS FOR WORLD ALZHEIMER’S DAY, SEPTEMBER 21LIFE GOES ON 2023: TWO MEMORIES, ONE STORY | News Release：2023 | Eisai Co., Ltd.
- “LEQEMBI® Intravenous Infusion” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan | News Release：2023 | Eisai Co., Ltd.
- EISAI ESTABLISHES THEORIA TECHNOLOGIES CO., LTD., A NEW DIGITAL BUSINESS COMPANY TO BUILD A DEMENTIA ECOSYSTEM | News Release：2023 | Eisai Co., Ltd.
- Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-010 Trial Evaluating LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | News Re
- EISAI LISTED FOR 22ND CONSECTUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT | News Release：2023 | Eisai Co., Ltd.
- ORGANIZATIONAL REFORM AND CHANGES OF CORPORATE OFFICERS | News Release：2023 | Eisai Co., Ltd.
- 「レカネマブ」について、アルツハイマー病の病理に対する効果、および皮下投与に関する最新の解析結果をアルツハイマー病協会国際会議2023（AAIC2023）において発表 | ニュースリリース：2023年 | エーザイ株式会社
- Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023 | News Release：2023 | Eisai Co., Ltd.
- EISAI TO PRESENT THE LATEST ALZHEIMER’S DISEASE PIPELINE AND RESEARCH, INCLUDING LECANEMAB AND ANTI-MTBR TAU ANTIBODY E2814, AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2023 | News Release：2023 | Eisai Co., Ltd.
- View more press releases Close
Social media about Eisai
- Eisai on Wikipedia, Google News & Yahoo Finance
- Eisai on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Yasushi Okada 
